Literature DB >> 34926777

"Post Mastectomy Pain Syndrome: A Systematic Review of Prevention Modalities".

Selcen S Yuksel1, Ava G Chappell1, Brandon T Jackson1, Annie B Wescott2, Marco F Ellis1.   

Abstract

BACKGROUND: Post-mastectomy pain syndrome (PMPS) is a surgical complication of breast surgery characterized by chronic neuropathic pain. The development of PMPS is multifactorial and research on its prevention is limited. The objective of this systematic review is to synthesize the existing evidence on interventions for lowering the incidence of persistent neuropathic pain after breast surgery.
METHODS: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a comprehensive search of the electronic databases of MEDLINE, Cochrane Library, Embase, CINAHL, PsycINFO, Web of Science, and ClinicalTrials.gov using a combination of database-specific controlled vocabulary and keyword searches. Two reviewers independently screened all unique records. Publications on chronic (>3-month duration) pain after breast cancer-related surgery were included. Studies were classified by modality.
RESULTS: Our literature search yielded 7092 articles after deduplication. We identified 45 studies that met final inclusion criteria for analysis, including 37 randomized-controlled trials. These studies revealed seven major intervention modalities for prevention of PMPS: physical therapy, mindfulness-based cognitive therapy, oral medications, surgical intervention, anesthesia, nerve blocks, and topical medication therapy.
CONCLUSION: High-quality data on preventative techniques for PMPS are required to inform decisions for breast cancer survivors. We present a comprehensive assessment of the modalities available that can help guide breast and reconstructive surgeons employ effective strategies to lower the incidence and severity of PMPS. Our review supports the use of multimodal care involving both a peripherally targeted treatment and centrally acting medication to prevent the development of PMPS.
© 2021 The Authors.

Entities:  

Keywords:  neuropathic pain; post-mastectomy pain syndrome; prevention; systematic review

Year:  2021        PMID: 34926777      PMCID: PMC8651974          DOI: 10.1016/j.jpra.2021.10.009

Source DB:  PubMed          Journal:  JPRAS Open        ISSN: 2352-5878


BACKGROUND

Persistent pain is a postoperative complication estimated to affect between 20% and 50% of mastectomy patients with considerable negative influence on quality of life. Post-mastectomy pain syndrome (PMPS) is a neuropathic condition defined as pain located in the anterior surface of the chest axilla, shoulder or upper half of the arm that persists for longer than 3 months after surgery., As treatment and diagnostic strategies advance, more women are expected to survive breast cancer, growing the population at risk for developing PMPS. Interventions are needed to prevent the development of this long-term, costly, and painful complication of breast cancer procedures. The pathophysiology of PMPS involves unrelieved inflammation and neuropathic pain. Possible contributors include sensitization of peripheral nociceptors and their primary afferent neurons, growth of neuromas on pain-sensing fibers, and sensitization of nerve cells in the brain. Further, severe acute postoperative pain results in increased incidence of persistent postoperative pain., Consequently, preventive and perioperative forms of analgesia and pharmacological agents may reduce the development of, or transition to, PMPS. Previous studies have reviewed associated risk factors for PMPS, including preoperative pain, axillary lymph node dissection (ALND), anxiety, younger age, and radiation therapy., Pharmacotherapy for prevention of general chronic pain after surgery has also been a focus of literature. However, a comprehensive review of interventions for the prevention of post-mastectomy neuropathic pain is lacking. In this study, we review the available modalities for prevention of the development of PMPS and assess their outcomes in order to guide optimal care for breast cancer patients.

MATERIALS AND METHODS

Our systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines as a framework to assess quality of evidence and risks of bias in the included studies. The protocol was registered with the National Institutes of Health Research database PROSPERO (ID = CRD42020167225).

Literature search and Study Appraisal

A research librarian (ABW) worked in collaboration with the review authors (SY, AC) to create a comprehensive search for identifying literature related to the neuropathic pain associated with breast cancer surgery. A search was developed for MEDLINE (PubMed), which was then translated for Cochrane Library databases (Wiley), Embase (Elsevier), CINAHL (Ebsco), PsycINFO (Ebsco), Web of Science (Clarivate), and ClinicalTrials.gov. All searches were conducted using a combination of database-specific controlled vocabulary and keyword searches without limits for date or publication type. English language filters were applied. Results were exported to a citation management software (EndNote) for deduplication. An example of the search strategy for PubMed is provided in Appendix A. References of eligible studies and review articles were reviewed to include studies not previously captured by the original search terms. To avoid selection bias, inclusion and exclusion criteria were agreed upon before data extraction and analysis (Table 1). Definition of the terms “chronic pain,” and “breast cancer-related procedures” was critical in creating the selection criteria (Appendix B). All unique records were uploaded into an online screening platform (Rayyan) for blinded independent screening by two reviewers, first through title and abstract screen and then through full-text review; disagreements were resolved by the senior author (MFE).
Table 1

Inclusion and Exclusion Criteria for Abstract and Full-Text Screening

Inclusion criteriaFull-text, original articlesWritten in the English languageReporting outcomes for interventions to prevent chronic pain after breast cancer-related surgeryObservational studies (case-control studies and cohort studies)Intervention studies, including RCTs
Exclusion criteriaReview articlesCase reports, case series, conference abstracts, book chapters, and letters to editorAnimal studies, cell studies, and cadaver studiesArticles with follow-up <3 monthsArticles regarding only treatment of chronic postoperative pain

RCTs – randomized-controlled trials

Inclusion and Exclusion Criteria for Abstract and Full-Text Screening RCTs – randomized-controlled trials

Data Extraction

Types of data extracted from each study included: (i) pain prevention modality, (ii) study design, (iii) number of patients, (iv) follow-up time, (v) outcome metrics, and (vii) major outcomes of intervention. Primary outcomes were limited to patient-reported pain characteristics, both quantitative and qualitative, and quality of life scores. Studies were organized based on thematic analysis of each pain prevention modality.

RESULTS

The initial literature search in the seven electronic databases yielded 7092 articles from the years 1946–2020 after deduplication. Following two rounds of screening, 45 studies fulfilled the eligibility criteria for inclusion, of which 37 were randomized-controlled trials (RCTs). Seven unique intervention modality groups were identified, with a range of reported outcomes (Table 2).
Table 2

Study characteristics of all included studies

Treatment ModalityReferenceDesign, N (# of patients)Intervention
Physical TherapyAmmitzbøll et al., 202011Double-blinded RCT, 1581-year progressive resistance training
De Groef et al., 201012Double-blinded RCT, 1438 sessions of myofascial therapy
Cognitive TherapyLacroix et al., 201913Prospective non-randomized study, 42Perioperative hypnosedation
Garssen et al., 201014RCT, 70Pre-surgical stress management training
Nerve BlocksBesch et al., 201019Retrospective comparative study, 191GA with pectoral nerve block
Fujii et al., 201820Double-blinded RCT, 80PECS II Block
De Cassai et al., 201918Prospective observational comparative study, 132PECS II block
Strazisar et al., 201415Prospective randomized study, 60Wound catheter with continuous infusion of local anesthetic
Mohamed et al., 201817Double-blinded RCT, 90Wound irrigation with bupivacaine plus 5, 10, or 15 mg morphine
Albi-Feldzer et al., 200016Double-blinded RCT, 236Wound infiltration with repeated injections of local anesthetic
Shimizu et al., 201523Retrospective cohort study, 46Perioperative ultrasound-guided TPVB
Karmakar et al., 201724Double-blinded RCT, 177Single injection or continuous infusion with catheter of TPVB
Kamal et al., 201925Double-blinded RCT, 80TPVB of bupivacaine with 0.5 mg/kg or 1 mg/kg ketamine
Kairaluoma et al., 200626Double-blinded RCT, 59Pre-incisional PVB
Elkaradawy et al., 201228RCT, 50Ultrasound-guided TPVB with GA
Ilfeld et al., 201827Double-blinded RCT, 60Ultrasound-guided continuous PVB catheter
Gacio et al., 201821Non-randomized prospective observational study, 66GA and single-injection PVB
Qian et al., 201922Double-blinded RCT, 184Ultrasound-guided single-injection multilevel TPVB
AnesthesiaCho et al., 201229Retrospective comparative study, 228Propofol vs. sevoflurane anesthesia
Lefebvre-Kuntz et al., 201532Prospective cohort study, 328Halogenated anesthetic vs. propofol
Grigoras et al., 201330Double-blinded RCT, 36Perioperative IV lidocaine
Terkawi et al., 201738Double-blinded RCT, 61Intraoperative IV lidocaine infusion
Kim et al., 201737Double-blinded RCT, 116Intraoperative systemic lidocaine vs. magnesium
Kendall et al., 201834Double-blinded RCT, 121Perioperative IV lidocaine
Khan et al., 2019*35Double-blinded RCT, 100Perioperative pregabalin and lidocaine infusion
Jain et al., 201236Double-blinded RCT, 69Intraoperative IV dexmedetomidine
Kang et al., 202033Double-blinded RCT, 168Perioperative IV ketamine
Sun et al., 201231Double-blinded RCT, 60Perioperative IV flurbiprofen axetil
Oral medicationsFassoulaki et al., 200239Double-blinded RCT, 67Perioperative oral mexiletine vs. gabapentin capsules
Lee et al., 201340Single-blinded RCT, 51Multimodal analgesia (perioperative pregabalin and PVB catheter of local anesthetic)
Vig et al., 201942Double-blinded RCT, 71Perioperative pregabalin
Reyad et al., 201943Double-blinded RCT, 181Perioperative pregabalin
Fassoulaki et al., 200144Double-blinded RCT, 96Perioperative mexiletine and regional ropivacaine block
Amr et al., 200946Double-blinded RCT, 150Perioperative gabapentin and venlafaxine
Khan et al., 2019*35Double-blinded RCT, 100Perioperative pregabalin and lidocaine infusion
Hah et al., 199645Double-blinded RCT, 41Perioperative gabapentin
Van Helmond et al., 201641Double-blinded RCT, 94Perioperative parecoxib injection and celecoxib
Fassoulaki et al., 200547Double-blinded RCT, 44Multimodal analgesia (Gabapentin, EMLA cream near incision, irrigation of brachial plexus block)
Na et al., 201848Double-blinded RCT, 83Intraoperative IV nefopam
Surgical interventionsSalmon et al., 199855Double-blinded RCT, 128Preservation of ICBN
Torresan et al., 200751Double-blinded RCT, 85Preservation of ICBN
Freeman et al., 200353Double-blinded RCT, 73Preservation of ICBN
Taira et al., 201454Non-blinded RCT, 140Preservation of ICBN
Tasmuth et al., 199950Retrospective observational study, 221High-volume surgical units vs. small-volume units
Yang et al., 201252Double-blinded RCT, 99Spray of HA–CMC gel onto surface of pectoralis major and serratus anterior muscles
Topical medicationsFassoulaki et al., 200056Double-blinded RCT, 45Intraoperative EMLA on sternal area

*Included in two categories

RCT – Randomized controlled trial

GA – Generalized anesthesia

TPVB – Thoracic paravertebral block

ICBN – Intercostal-brachial nerve

HA–CMC – Hyaluronic acid–carboxymethyl cellulose

IV – Intravenous

Study characteristics of all included studies *Included in two categories RCT – Randomized controlled trial GA – Generalized anesthesia TPVB – Thoracic paravertebral block ICBN – Intercostal-brachial nerve HA–CMC – Hyaluronic acid–carboxymethyl cellulose IV – Intravenous

Physical Therapy

Two double-blinded RCTs evaluated the effects of physical therapy (PT) on incidence and severity of PMPS in women undergoing breast cancer surgery with ALND, with little effect., The follow-up time in both studies was 12 months, and the total study population was 301 patients. Ammitzbøll et al. reported that a 1-year progressive resistance training program initiated at 3 weeks after breast cancer surgery with ALND conferred no benefit over usual care in reducing chronic pain incidence or intensity. Similarly, an 8-week myofascial therapy program had no added benefit compared with standard PT.

Cognitive Therapy

Two studies on the efficacy of cognitive behavioral therapy in the prevention of PMPS met inclusion criteria, one of which was an RCT., The mean follow-up time for both studies was 26 months, and the total study population was 112 patients. Lacroix et al. reported that in 42 patients undergoing mastectomy with ALND, perioperative hypnosedation led to significantly lower incidence of PMPS at 4 years postoperatively compared with general anesthesia (GA) (P = 0.008). Pre‐surgical stress management training (SMT) did not significantly influence postoperative pain or anxiety after 3 months compared with control.

Nerve Blocks

Fourteen studies on the efficacy of perioperative nerve blocks in the prevention of PMPS met inclusion criteria (Table 3). Eight of these were double-blinded RCTs, while the rest comprised two retrospective cohort studies, two prospective randomized studies, and two prospective observational comparative studies. The mean follow-up time across all studies was 8 months, and the total study population involved 1511 patients.
Table 3

Nerve Block Studies

ReferenceProcedureInterventionFollow-up (mo), Avg (Range)Outcome measuresFindings
Besch et al., 201019Breast cancer surgeryPerioperative GA with pectoral nerve block6Presence of pain (Breast Cancer Pain Questionnaire), Pain intensityPectoral block had no effect on incidence nor severity of persistent post-surgical pain
De Cassai et al., 201918Mastectomy or lateral quadrantectomyPECS II block12Presence of pain, intensity of pain (NRS)PECS II decreased incidence of chronic pain only for 3 months compared to GA alone (P = 0.039). It did not decrease pain intensity.
Fujii et al., 201820MastectomyPECS II block6Presence of pain, pain intensity (NRS), health-related QOL (EQ-5D-3L questionnaire)PECS II reduced incidence of moderate and severe chronic pain compared to serratus plane block (P = 0.02).
Strazisar et al., 201415Breast cancer surgery with ALNDWound catheter with continuous infusion of local anesthetic6Presence of painInfusion of local anesthetic did not significantly decrease incidence of neuropathic pain compared to standard IV analgesia (20% vs. 40%, P = 0.09)
Mohamed et al., 201817Modified radical mastectomy with ALNDWound irrigation with bupivacaine plus 5, 10 or 15 mg morphine3Location, intensity, nature and duration of pain, analgesic medication use, LANSS Pain ScaleThe lowest mean LANSS score was recorded in the Morphine 15 group compared with Morphine 5 and Morphine 10 (P < 0.006).
Albi-Feldzer et al., 200016Breast cancer surgeryWound infiltration with repeated injections of local anesthetic12Presence of pain, pain intensity at rest and movement, pain interference (BPI), neuropathic pain (DN4)Ropivacaine wound infiltration did not decrease chronic pain intensity or incidence.
Gacio et al., 201821Major resection for breast cancerSingle TPVB injection6
Pain intensity at rest and with movement in ipsilateral arm (VAS), neuropathic pain (DN3), QOL (EORTC QLQ-C30)Single-injection PVB had no effect on intercostobrachial neuralgia (P = 0.3).
Kairaluoma et al., 200626Conservative breast surgery for cancer with SENTINEL lymph node biopsySingle TPVB injection12Presence of pain, pain intensity at movement and rest (NRS), pain characteristicsPVB lowered pain incidence (P = 0.003), intensity at rest (P = 0.011) and movement (P = 0.003).
Shimizu et al., 201523Breast cancer surgeryUltrasound-guided single TPVB injection15 (13, 17)Pain intensity (VRS)TPVB significantly lowered incidence of chronic pain (P = 0.039).
Karmakar et al., 201724Modified radical mastectomy with ALNDSingle injection or continuous infusion with catheter of TPVB6Incidence of pain, pain severity (VRS) at rest and during movement, health-related QOL, Chronic Pain Symptom and Sign ScoreNo difference in incidence of chronic pain between groups (P = 0.79). Patients receiving TPVB had lower chronic pain scores (P < 0.05) and had fewer symptoms of chronic pain (P0.01).
Elkaradawy et al., 201228Conservative breast surgery for cancerUltrasound-guided TPVB with GA9Neuropathic pain (NPS), Pain intensity (NRS)TPVB decreased pain intensity (P0.05).
Ilfeld et al., 201827Uni- or bilateral mastectomyUltrasound- guided continuous PVB catheter12Presence of pain, pain intensity and interference (BPI)PVB catheter significantly decreased incidence (P = 0.011) and intensity of pain (P = 0.007).
Qian et al., 201922Unilateral partial mastectomyUltrasound-guided single-injection multilevel TPVB6Presence of pain, pain intensity and interference (BPI)PVB significantly reduced severity (P < 0.001). and incidence (P = 0.03) of chronic pain.
Kamal et al., 201925Modified radical mastectomy and ALNDUltrasound-guided multilevel TPVB with 0.5 mg/kg or 1 mg/kg ketamine3DN4 questionnaire for chronic neuropathic painNo difference in mean DN4 scores between control, 0.5 mg/kg and 1 mg/kg ketamine (P = 0.132)

NRS – Numerical rating scale

QOL – Quality of life

LANSS- Leeds Assessment of Neuropathic Symptoms and Signs

BPI – Brief Pain Inventory

DN4 – Douleur neuropathique 4

TPVB – Thoracic paravertebral block

VAS – Visual analogue scale

DN3 – Douleur neuropathique 3

VRS – Verbal rating scale

Nerve Block Studies NRS – Numerical rating scale QOL – Quality of life LANSS- Leeds Assessment of Neuropathic Symptoms and Signs BPI – Brief Pain Inventory DN4 – Douleur neuropathique 4 TPVB – Thoracic paravertebral block VAS – Visual analogue scale DN3 – Douleur neuropathique 3 VRS – Verbal rating scale Wound infiltration with local analgesia, whether through continuous infusion with a wound catheter or through repeat injections, was ineffective across two double-blinded RCTs. , In a third study by Mohamed et al., higher doses of morphine for wound irrigation were more effective in decreasing intensity of chronic pain (P < 0.006). Three studies with a total of 403 patients investigated the utility of pectoral nerve blocks (PECS) in preventing chronic pain after breast cancer-related surgery. 18, 19, 20 While PECS administered with GA was ineffective, the results of PECS II were equivocal; one study found its benefit versus GA to be limited to 3 months, and another found that it reduced incidence of moderate/severe chronic pain when compared to serratus plane block (P = 0.02)., Eight studies with a total of 722 patients investigated the effects of thoracic paravertebral blocks (TPVBs) on reducing chronic pain after breast cancer.21, 22, 23, 24, 25, 26, 27, 28 Five of these studies used ultrasound guidance for TPVB administration. While one study found no effect on intercostobrachial neuralgia, six studies found that TPVBs reduced incidence and intensity of chronic pain. Single injection versus continuous infusion with a catheter did not differ in efficacy. Ketamine administration with TPVB had no effect.

General Anesthesia

Ten studies on the efficacy of anesthesia in the prevention of PMPS met inclusion criteria (Table 4).29, 30, 31, 32, 33, 34, 35, 36, 37, 38 These included one retrospective study, one prospective study, and eight double-blinded RCTs. The mean follow-up time for all ten studies was 9 months, and the total study population was 1287 patients.
Table 4

Anesthesia Studies

ReferenceProcedureInterventionFollow-up (mo), Avg (Range)Outcome measuresFindings
Cho et al., 201229Breast cancer surgeryPropofol vs. sevoflurane anesthesia39 (30, 48)Presence of pain, pain intensity (NRS), pain interference with daily lifeSevoflurane resulted in higher incidence of chronic pain compared to propofol (P = 0.007), but not pain intensity.
Lefebvre-Kuntz et al., 201532Breast cancer surgeryPropofol vs. halogenated anesthetic6Presence of pain, Neuropathic pain (DN4, Neuropathic Pain Symptom Inventory), pain intensity (VAS),Type of general anesthetic had no effect on incidence nor intensity of pain.
Grigoras et al., 2013Mastectomy or wide local excision with ALNDIV lidocaine infusion3Presence of pain, intensity of pain (SF-MPQ, VAS) character of pain, interference with daily lifeLidocaine resulted in lower pain incidence (P = 0.031) and intensity (0.025) compared to control.
Terkawi et al., 201738MastectomyIV lidocaine infusion6Presence of pain, pain intensity (NRS), pain characteristicsLidocaine was associated with a 20-fold decrease in incidence of CPSP compared to control (P = 0.013).
Kim et al., 201737Breast cancer surgerySystemic lidocaine infusion vs. magnesium3Presence of pain, pain intensity and quality (Korean SF-MPQ)Lidocaine significantly decreased pain intensity compared to control (P = 0.046), but had no effect on chronic pain incidence. Magnesium had no effect.
Kendall et al., 201834Breast cancer surgeryIV lidocaine infusion6Presence of pain, pain intensity (NRS, BPI, SF-MPQ), neuropathic pain (S-LANSS)Lidocaine reduced pain incidence (P = 0.04) compared to control and had no effect on intensity.
Khan et al., 2019*35Unilateral or bilateral mastectomy or lumpectomyPerioperative pregabalin and lidocaine infusion3Presence of pain, pain intensity (BPI, SF-MPQ2), neuropathic pain (DN4)Lidocaine decreased incidence of persistent neuropathic pain (P = 0.049) compared to control, but not intensity. Pregabalin had no effect.
Sun et al., 201231Mastectomy with ALNDPerioperative IV flurbiprofen axetil12Presence of pain, pain intensity (NRS), nature of painFlurbiprofen axetil resulted in lower pain incidence for 6 months postoperatively, but not 12 months. It significantly lowered pain intensity (P < 0.05).
Kang et al., 202033Unilateral breast cancer surgeryIV ketamine6Presence of pain, pain intensity at rest and movement (NRS), Neuropathic pain (DN4)Ketamine did not reduce pain intensity compared with control. Pain incidence was lower at 3 months, but not 6.
Jain et al., 201236Breast cancer surgeryIV dexmedetomidine3Presence of pain, pain intensity (BPI, SF-MPQ2)Dexmedetomidine decreased pain intensity (P < 0.001) and incidence (P < 0.001) compared with control.

NRS – Numerical rating scale

DN4 – Douleur neuropathique 4

VAS – Visual analogue scale

SF-MPQ – Short-form McGill Pain Questionnaire

BPI – Brief Pain Inventory

S-LANSS – Self-administered Leeds Assessment of Neuropathic Symptoms and Signs

QOL – Quality of life

IV – Intravenous

Anesthesia Studies NRS – Numerical rating scale DN4 – Douleur neuropathique 4 VAS – Visual analogue scale SF-MPQ – Short-form McGill Pain Questionnaire BPI – Brief Pain Inventory S-LANSS – Self-administered Leeds Assessment of Neuropathic Symptoms and Signs QOL – Quality of life IV – Intravenous A retrospective study found that incidence of chronic pain was significantly higher in the sevoflurane anesthesia group compared with the propofol anesthesia group (P = 0.007). However, a multicenter prospective study by Lefebvre-Kuntz et al. with a greater sample size found no difference between propofol and other halogenated agent anesthetics. Neither study found an effect of anesthesia type on pain intensity. Across five studies, intravenous (IV) lidocaine infusion significantly decreased chronic pain incidence, intensity, or both.,,,, Pregabalin and magnesium were both comparatively ineffective. , The remaining three studies in this cohort investigated several other anesthetic agents. Intraoperative low-dose ketamine reduced pain incidence at 3 months postoperatively compared with a control, but these results did not continue through 6 months. IV flurbiprofen axetil significantly decreased both incidence of pain and pain scores at 6 months postoperatively compared with a control. Perioperative infusion of dexmedetomidine significantly decreased the incidence and intensity of chronic pain.

Oral Medications

Eleven RCTs regarding the efficacy of oral medications met inclusion criteria (Table 5).,39, 40, 41, 42, 43, 44, 45, 46, 47, 48 Of these, ten were double-blinded RCTs. Across all studies, the mean follow-up time was 5 months, and there were 978 total patients.
Table 5

Oral Medication Studies

ReferenceProcedureInterventionFollow-up (mo), Avg. (Range)Outcome measuresFindings
Fassoulaki et al., 200144Modified radical mastectomy or lumpectomy with ALNDMexiletine and regional ropivacaine block3Presence of pain, pain intensityOral mexiletine, regional block nor their combination decreased incidence or intensity of chronic pain compared with control.
Fassoulaki et al., 200239Breast surgery for cancerMexiletine vs. gabapentin3Presence of pain, pain intensity (NRS)Neither mexiletine nor gabapentin affected pain incidence or intensity compared with control.
Hah et al., 199645Unilateral/ bilateral mastectomy or breast lumpectomyGabapentin12Presence of pain, pain intensity (BPI)Gabapentin did not decrease incidence of pain compared with control.
Amr et al., 200946Partial or radical mastectomy with ALNDGabapentin and venlafaxine6Presence of pain, pain intensity (VAS), pain characteristicsVenlafaxine decreased pain intensity (P < 0.0001) and incidences of burning and stabbing pain compared with gabapentin and control.
Fassoulaki et al., 200547Breast cancer surgeryMultimodal analgesia (oral gabapentin, EMLA cream near incision, irrigation of brachial plexus block)6Presence of pain, pain intensityMultimodal analgesia intervention did not decrease incidence of chronic pain.
Vig et al., 201942Modified radical mastectomyPregabalin3Presence of pain, pain intensity (NRS)Pregabalin did not decrease incidence nor intensity of chronic pain compared with control.
Reyad et al., 201943Modified radical mastectomy or conservative breast surgery with ALNDPregabalin6Presence of pain, neuropathic pain (GSNP), pain intensity at rest and movement (VAS)Pregabalin decreased incidence (P < 0.001) and intensity (P = 0.002) of neuropathic pain compared with control.
Khan et al., 2019*35Unilateral or bilateral mastectomy or lumpectomyPregabalin and lidocaine infusion3Presence of pain, pain intensity (BPI, SF-MPQ2), neuropathic pain (DN4)Lidocaine decreased incidence of persistent neuropathic pain (P = 0.049) compared with control, but not severity. Pregabalin had no effect.
Lee et al., 201340Breast surgery with ALNDMultimodal analgesia (pregabalin and PVB catheter of local anesthetic)3Presence of pain, pain characteristics (SF-MPQ)Multimodal analgesic regimen did not decrease pain incidence compared with control.
Van Helmond et al., 201641Breast cancer surgeryParecoxib injection and oral celecoxib12Presence of pain, pain intensity at rest and during movement (VAS), electric pain and pressure pain tolerance thresholdsCOX-2 inhibition had no effect on pain intensity compared with control.
Na et al., 201848Lumpectomy with ALND or SLNBIV nefopam3Pain intensity (NRS)Nefopam decreased
incidence of chronic pain (P = 0.04), but had no effect on pain intensity compared with control.

NRS – Numerical rating scale

BPI – Brief Pain Inventory

VAS – Visual analogue scale

GSNP- Grading system for neuropathic pain

SF-MPQ – Short-form McGill Pain Questionnaire

DN4 – Douleur neuropathique 4

Oral Medication Studies NRS – Numerical rating scale BPI – Brief Pain Inventory VAS – Visual analogue scale GSNP- Grading system for neuropathic pain SF-MPQ – Short-form McGill Pain Questionnaire DN4 – Douleur neuropathique 4 Four studies testing the efficacy of gabapentin showed negative results, whether it was administered alone, with another medication, or as part of a multimodal analgesia course.,45, 46, 47 Four studies evaluated the efficacy of pregabalin.,,, While it had no effect on incidence or intensity of chronic pain in three studies, Reyad et al. found that the medication decreased both incidence and intensity of chronic pain at 6 months postoperatively. Various other medications had mixed results in reducing PMPS incidence. Mexiletine and COX2 inhibitors were both ineffective, while venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), significantly reduced incidence and intensity of chronic pain at 6 months postoperatively.,,, Preventative IV nefopam significantly decreased the incidence, but not intensity, of chronic pain.

Surgical Techniques

Six articles focusing on the potential role of surgical techniques in prevention of chronic neuropathic pain after breast cancer-related surgery were included (Table 6).50, 51, 52, 53, 54, 55 These consisted of four double-blinded RCTs, one non-blinded RCT, and one retrospective observational study. Across all studies, the mean follow-up time was 16 months and a total of 746 patients were included.
Table 6

Surgical Intervention Studies

ReferenceProcedureInterventionFollow-up (mo), Avg (Range)Outcome measuresFindings
Salmon et al., 199855Mastectomy or conservative breast cancer surgeryPreservation of ICBN16 (10, 22)Presence of pain or sensitivity in region of the ICBNICBN preservation had no effect on pain.
Torresan et al., 200751Axillary lymphadenectomyPreservation of ICBN3Presence, intensity and type of sensitivity deficits and painICBN preservation decreased incidence of anesthesia, hypoesthesia or hyperesthesia (P < 0.01).
Freeman et al., 200353Breast cancer surgeryPreservation of ICBN36 (32-38)Sensation for light touch, presence of neuromasPreservation of ICBN had no effect on pain.
Taira et al., 201454Breast cancer surgeryPreservation of ICBN24Presence of dysesthesia, paresthesia and pain sensation in upper arm, health related QOL (FACT-B)Preservation of ICBN had no effect on incidence or severity of pain compared to dissection.
Yang et al., 201252Total mastectomySpray of HA-CMC gel onto surface of pectoralis major and serratus anterior muscles6Presence of motion-related pain and intensity of pain (NRS), DASH questionnaireHA-CMC decreases pain intensity related to flexion (P < 0.001) and abduction (P = 0.034) compared to control.
Tasmuth et al., 199950Unilateral breast cancer surgery with axillary clearanceHigh-volume surgical units (HVU) vs. small-volume units (LVU)12Presence of pain, pain intensity (VAS, Finnish MPQ), interference with sleepPatients in LVU had higher incidence of chronic pain (P < 0.05).

ICBN - Intercostal-brachial nerve

QOL – Quality of life

FACT-B – Functional Assessment of Cancer Therapy – Breast

NRS – Numerical rating scale

DASH – Disabilities of the arm, shoulder, and hand

VAS – Visual analogue scale

MPQ- McGill Pain Questionnaire

Surgical Intervention Studies ICBN - Intercostal-brachial nerve QOL – Quality of life FACT-B – Functional Assessment of Cancer Therapy – Breast NRS – Numerical rating scale DASH – Disabilities of the arm, shoulder, and hand VAS – Visual analogue scale MPQ- McGill Pain Questionnaire Preservation of the intercostal-brachial nerve (ICBN) was discussed in four RCTs. ,53, 54, 55 Three of these studies concluded that preserving the ICBN conferred no significant differences in incidence or intensity of chronic pain. 53–55 However, Torresan et al. found that ICBN preservation decreased overall incidence of anesthesia, hypoesthesia, or hyperesthesia. A mixed solution of sodium hyaluronate and carboxymethylcellulose (HA–CMC) on the surface of the pectoralis major and serratus anterior muscles resulted in significantly lower pain intensity related to flexion and horizontal abduction at 6 months postoperatively. According to an observational study, pain at 1 year was less common in patients receiving breast cancer surgery at high-volume surgical units than low-volume ones (P <0.05).

Topical Medication Therapy

A double-blinded RCT of 45 patients evaluating topical medication for prevention of PMPS concluded that perioperative application of eutectic mixture of local anesthetics (EMLA) cream on the sternal, supraclavicular, and axillary area significantly decreased incidence (P = 0.002) and intensity (P = 0.003) of pain in the chest wall and axilla 3 months postoperatively.

DISCUSSION

Summary of main results

This systematic review aimed to identify effective interventions for prevention of PMPS. Interventions were categorized into seven unique modalities that could, in turn, be categorized based on pathophysiologic targets that are either peripherally or centrally mediated. Peripheral nerve sensitization is caused by iatrogenic injury and compression by scar tissue, which reduce firing thresholds of nociceptors’ terminals in the axilla and chest wall and their associated primary afferent neurons. Other interventions target the central nervous system (CNS) by interfering with neurotransmission. This prevents maladaptive central sensitization caused by repeated stimulation of nociceptive pathways. Interventions for peripheral sensitization (topical medication, systemic and local anesthesia, peripheral nerve surgery) Of all forms of anesthesia, perioperative IV lidocaine showed the most positive results in our review, with multiple RCTs demonstrating its efficacy in reducing incidence and severity of PMPS. Systemic administration of local anesthetics has analgesic, anti-inflammatory, and anti-hyperalgesic effects, simultaneously targeting peripheral nociceptors and central sensitization. , However, Kendall et al. hypothesize that relying on a binary yes/no criterion to detect persistent pain rather than a validated pain instrument, as all but one of these studies do, may lead to overestimation of lidocaine's efficacy. Administration of local anesthetic suppresses afferent nociceptive signals and inflammatory reaction after nerve injury, but appears limited in its capacity to prevent chronic pain. This indicates that while there is ample evidence for severe acute postoperative pain being a risk factor for development of PMPS, modulation of acute pain alone is not sufficient to prevent chronic pain. Meanwhile, topical EMLA seems to significantly reduce the incidence and severity of PMPS, whether through anesthetic effect on cutaneous areas where injured nerves project, or due to systemic uptake. Intercostobrachial neuralgia due to sectioning of the ICBN is the most common cause of post-mastectomy chronic pain, and a common consequence of ALND., Across multiple studies, ALND increases the incidence of chronic pain compared to sentinel lymph node biopsy (SLND) and no axillary procedures.62, 63, 64, 65, 66 While the efficacy of ICBN preservation is widely debated in the literature, it has no effect on PMPS based on the findings of this review. Importantly, evidence has shown that breast reconstruction, whether implant or autologous, does not increase the incidence of PMPS despite additional tissue dissection and potential donor site morbidity. Long-term prospective cohort studies with standardized pain management among patients to compare different approaches to breast reconstruction are necessary.

Interventions for central sensitization (psychiatric treatment, oral medications)

Cortical reorganization plays an essential role in neuropathic pain after mastectomy. Anxiety, depression, and pain catastrophizing increase intensity of pain perception in the acute postsurgical period and are associated with development of PMPS.68, 69, 70 Behavioral cognitive therapy may help alter perception of noxious stimuli. Accordingly, perioperative hypnosis and pre-surgical stress management performed appear to be effective in preventing PMPS. Medications targeting central sensitization showed variable benefits in this review, with wide ranges of drug doses and administration duration across studies. Nefopam and venlafaxine were both effective. Despite its efficacy in treatment of PMPS, gabapentin was ineffective in pain prevention, while results of pregabalin studies were equivocal. Gabapentinoids, such as gabapentin and pregabalin, interfere with afferent pain signals by inhibiting glutamate release in the dorsal horn of the spinal cord. Nefopam has properties of a monoamine reuptake inhibitor and an NMDA receptor antagonist, preventing pain signal transmission to secondary afferent neurons. Tricyclic antidepressants (TCAs), SSNRIs, such as venlafaxine, and SSNRIs inhibit pain transmission by: 1) binding to α2-adrenergic receptors in the dorsal horn of the spinal cord, preventing release of excitatory neurotransmitters that lead to pain perception and 2) increasing noradrenaline levels at the locus coeruleus of the brainstem, improving the function of an impaired descending noradrenergic inhibitory system. While our review found COX-2 inhibitors to be ineffective, IV flurbiprofen axetil, a nonselective COX inhibitor with a high affinity for inflammatory tissues due to its composition as emulsified lipid microspheres, effectively reduced pain incidence, indicating that blocking inflammatory responses plays a role in preventing PMPS. This supports the idea that therapy limited to pre- and intraoperative periods are likely to be insufficient for pain prevention due to the inflammatory reaction of damaged tissue providing a source of sensory signals that could induce central sensitization, even if it was prevented during the operation. Given the close link between acute postoperative pain and chronic pain, medications that reduce perioperative anxiety may play a role in PMPS prevention. Ketamine has both mood stabilization and analgesic effects achieved through NMDA receptor blockade and decreased reuptake of serotonin and norepinephrine. However, it was shown to be ineffective for PMPS prevention in this review, both alone and when administered with TPVB, indicating that targeting central sensitization alone is insufficient.

Interventions for central sensitization (nerve blockade)

Nerve blocks prevent integration of nociceptive impulses to the CNS, preventing the development of hyperalgesia and chronic pain. We conclude that single injection and continuous TPVB are effective in reducing severity and incidence of chronic pain. Ultrasound-guided thoracic interfascial plane blocks are alternatives to PVBs. The PECS II block entails two interfascial injections of local anesthetic between the pectoralis major and minor muscles, while the serratus plane block is a single injection between the serratus anterior and latissimus dorsi muscles. As found in our review, PECS II was effective compared with serratus plane block; however, its efficacy compared with that of GA was not significant after 3 months. Considering the apparent positive results of nerve blocks for chronic pain, RCTs are necessary to compare the efficacy of PVB with PECS II block, and future work is needed to elucidate the exact medications and dosages necessary for optimal results.

Interventions for musculoskeletal dysfunction

Breast surgery often results in a decrease in motility of myofascial tissues relative to each other, creating trigger points (TrPs) and contributing to chronic postoperative upper limb pain. The aim of PT is to manually release these TrPs and tissue adhesions. However, our review found no benefit of myofascial therapy. Progressive resistance training was similarly ineffective. These results indicate a need to identify subgroups of patients for whom PT would be effective, specifically those whose pain is contributed to by myofascial dysfunctions. While pectoralis tightness and pain from adhesion can be prevented by stretching exercises, this intervention poses a risk for seroma formation. The effectiveness of HA–CMC as an alternative seen in our review shows promise in attenuating early postoperative adhesions that may evolve into chronic pain.

Limitations of this study

Lack of access to potentially negative studies that remain unpublished may be a source of publication bias that our review strategy was unable to overcome. Another potential limitation of this study is reviewer bias. To minimize this bias, two independent reviewers screened articles in the method supported by the PRISMA-P systematic review protocol. Due to the heterogeneity of patient populations, follow-up times and treatments across studies, subgroup analysis was not feasible. Future studies are necessary to guide treatment recommendations tailored to specific patient profiles.

CONCLUSION

This comprehensive review of strategies for prevention of chronic pain after breast cancer-related surgery highlights several effective intervention modalities. As PMPS is a phenomenon mediated through multiple mechanisms, our review supports the use of a multimodal intervention involving preoperative nerve block, intraoperative lidocaine infusion and postoperative medications to prevent the onset of pain hypersensitivity. Future research should evaluate the potential of personalized and multimodal prevention strategies that utilize combination therapy to more effectively prevent chronic post-mastectomy pain. Further, that many medications are effective for treatment of acute postoperative pain, but not prevention of chronic neuropathic pain after breast cancer surgery highlights the need for further investigation into the pathogenesis of post-mastectomy pain and novel pharmacological targets of prevention. Fig. 1.
Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram illustrating the flow of information through phases of the systematic review.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram illustrating the flow of information through phases of the systematic review.

Declaration of Competing Interest

Dr. Ellis, Ms. Yuksel, Dr. Chappell, Dr. Jackson and Ms. Wescott have nothing to disclose.
  69 in total

1.  Impact of the preservation of the intercostobrachial nerve in axillary lymphadenectomy due to breast cancer.

Authors:  Renato Zocchio Torresan; César Cabello; Délio Marques Conde; Henrique Benedito Brenelli
Journal:  Breast J       Date:  2003 Sep-Oct       Impact factor: 2.431

2.  Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial.

Authors:  James S Khan; Nicole Hodgson; Stephen Choi; Susan Reid; James E Paul; Nicole J Look Hong; Claire Holloway; Jason W Busse; Ian Gilron; D Norman Buckley; Michael McGillion; Hance Clarke; Joel Katz; Sean Mackey; Ronen Avram; Kayla Pohl; Purnima Rao-Melacini; P J Devereaux
Journal:  J Pain       Date:  2019-03-05       Impact factor: 5.820

3.  Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer.

Authors:  Argyro Fassoulaki; Argyro Triga; Aikaterini Melemeni; Constantine Sarantopoulos
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 5.108

4.  The effect of sentinel node selective axillary lymphadenectomy on the incidence of postmastectomy pain syndrome.

Authors:  R Miguel; A M Kuhn; A R Shons; P Dyches; M D Ebert; E S Peltz; K Nguyen; C E Cox
Journal:  Cancer Control       Date:  2001 Sep-Oct       Impact factor: 3.302

5.  Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action.

Authors:  W Koppert; N Ostermeier; R Sittl; C Weidner; M Schmelz
Journal:  Pain       Date:  2000-03       Impact factor: 6.961

6.  A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients.

Authors:  Guy H Montgomery; Dana H Bovbjerg; Julie B Schnur; Daniel David; Alisan Goldfarb; Christina R Weltz; Clyde Schechter; Joshua Graff-Zivin; Kristin Tatrow; Donald D Price; Jeffrey H Silverstein
Journal:  J Natl Cancer Inst       Date:  2007-08-28       Impact factor: 13.506

7.  Preservation versus section of intercostal-brachial nerve (IBN) in axillary dissection for breast cancer--a prospective randomized trial.

Authors:  R J Salmon; Y Ansquer; B Asselain
Journal:  Eur J Surg Oncol       Date:  1998-06       Impact factor: 4.424

8.  Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.

Authors:  Noud van Helmond; Monique A Steegers; Gertie P Filippini-de Moor; Kris C Vissers; Oliver H Wilder-Smith
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 9.  Analgesic Mechanisms of Antidepressants for Neuropathic Pain.

Authors:  Hideaki Obata
Journal:  Int J Mol Sci       Date:  2017-11-21       Impact factor: 5.923

10.  Preoperative ultrasound-guided multilevel paravertebral blocks reduce the incidence of postmastectomy chronic pain: a double-blind, placebo-controlled randomized trial.

Authors:  Bin Qian; Shiwei Fu; Yusheng Yao; Daoyi Lin; Li Huang
Journal:  J Pain Res       Date:  2019-02-05       Impact factor: 3.133

View more
  1 in total

1.  Exclusion of older adults from clinical trials in cancer-related pain.

Authors:  Krzysztof Krysa; Ewa Kowalczyk; Jan Borysowski; Mieszko Lachota; Tomasz Pasierski
Journal:  Front Med (Lausanne)       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.